Data showing the ability of omacetaxine to kill leukemic stem cells in mouse models with drug-resistant chronic myelogenous leukemia (CML) are the subject of an advance online publication in the journal Leukemia, ChemGenex Pharmaceuticals Limited (ASX:CXS and NASDAQ:CXSP) announced today. The findings of this study provide new insights into the problem of minimal residual disease and may open the door to the development of a curative treatment strategy for some patients with CML.
Full article >>
Thursday, March 26, 2009
Data suggesting that omacetaxine can eradicate leukemic stem cells may offer a breakthrough for CML
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment